SLU-PP-332

• Dry fill capsules (250 mcg, 60 count, 15 mg total)
• 30 mL liquid solution (500 mcg per mL, 15 mg total)
• 30 mL liquid solution (40 mg per mL, 1.2 g total)
• 30 mL liquid solution (100 mg per mL, 3 g total)
• 10 mL aliquot vial (25 mg per mL, 250 mg total)
• 1 gram powder

• ERR binding and transcriptional activation that shifts cellular programs toward higher oxidative metabolism and energy production signaling.
• Mitochondrial biogenesis signaling that may increase mitochondrial content and capacity, expanding the cellular machinery available for fat oxidation.
• Skeletal muscle specific fat oxidation support, with reports of increased endurance capacity and greater lipid utilization within muscle fibers in model settings.
• AMPK linked energy stress signaling and autophagy related pathways that are conceptually similar to caloric restriction style signals in some mechanistic discussions.
• Cardiometabolic support rationale based on ERR pathway relevance in heart function and protection signaling, which is why ERR activation is discussed beyond cosmetic outcomes.

SLU-PP-332 is commonly studied for

• Improved fat oxidation signaling and oxidative metabolism markers in model contexts.
• Endurance and aerobic adaptation like effects in research discussions, often described as exercise mimic style signaling rather than acute thermogenesis.
• Metabolic health signals that may include improved insulin sensitivity and favorable shifts in energy expenditure in certain models.
• Organ pathway interest including liver related signals in fatty liver models and kidney protection signals in select disease contexts.
• Body fat reduction signals in obesity model contexts, typically framed as a downstream effect of increased oxidative capacity and metabolic efficiency.

• SLU-PP-332 is frequently described in review discussions as having no significant side effects reported but that should be interpreted narrowly. Lack of reported adverse events in limited model settings does not establish long term safety in humans.
• Because ERR signaling touches multiple metabolically active organs, tolerability should be treated as dose dependent and context dependent, and conservative interpretation is warranted.